NCT02738073

Brief Summary

Tranexamic acid (TA) inhibits fibrinolysis by binding to lysine binding-sites of plasminogen to fibrin. Fibrinolysis is stimulated by surgical trauma, and the administration of TA has been shown effective in decreasing blood loss both intra-operatively and in the immediate post-operative period in elective hip and knee arthroplasty patients. Both the timing and dosing of TA has been investigated in these patients. Subsequent blood transfusion rate has also been shown to decrease as result of TA administration. Despite the support for TA utilization that exists in the arthroplasty literature, the data is scarce regarding its administration during surgical treatment of hip fractures. This is patient population who is at high risk for transfusion due to symptomatic post-operative anemia. This study aims to investigate whether TA's advantageous effects in the arthroplasty patient population can be extrapolated to the more unstable, heterogeneous hip fracture patient population. If the study is able to show a difference in blood loss and transfusion requirement, the long term implications of this with regards to cost and mortality can be significant.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 10, 2014

Completed
2.2 years until next milestone

First Posted

Study publicly available on registry

April 14, 2016

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2017

Completed
Last Updated

April 14, 2016

Status Verified

April 1, 2016

First QC Date

February 10, 2014

Last Update Submit

April 8, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • calculation of blood loss during the perioperative period

    This study aims to investigate the effect of tranexamic acid (TA) on blood loss and transfusion requirement during the perioperative period in patients who are admitted to the hospital with fracture of the hip and undergo surgical treatment. Both the drop in hemoglobin level from time of surgery (T0 being defined as just prior to surgery, while the patient waits in surgical holding area) over the subsequent several days, as well as post-operative transfusion rate, will be measured. The researchers' hypothesis is that both the hemoglobin drop and the subsequent transfusion requirement in patients who receive TA will be less than those who received saline placebo.

    participants will be followed for the duration of hospital stay, an expected average of 2-3 days

Study Arms (2)

Control

PLACEBO COMPARATOR
Drug: Control: Saline

Interventional

ACTIVE COMPARATOR
Drug: Tranexamic Acid

Interventions

Control
Interventional

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients admitted to Bryn Mawr Hospital with fracture of the femoral neck, intertrochanteric region, or subtrochanteric region of the femur will be considered for the study.

You may not qualify if:

  • age under 18
  • allergy to TA
  • known current or history of venous thromboembolism (VTE)
  • history of known coagulopathy or bleeding disorder
  • current subarachnoid hemorrhage
  • previous history of seizures
  • current use of estrogen/progesterone therapy
  • renal failure defined as creatinine clearance less than 30 ml/min4
  • multiple fractures
  • pregnant or breastfeeding women
  • planned nonoperative management of the fracture

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bryn Mawr Hospital

Bryn Mawr, Pennsylvania, 19010, United States

RECRUITING

MeSH Terms

Conditions

Hip Fractures

Interventions

Tranexamic Acid

Condition Hierarchy (Ancestors)

Femoral FracturesFractures, BoneWounds and InjuriesHip InjuriesLeg Injuries

Intervention Hierarchy (Ancestors)

Cyclohexanecarboxylic AcidsAcids, CarbocyclicCarboxylic AcidsOrganic Chemicals

Central Study Contacts

Tiffany Morrison, MS, CCRP

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 10, 2014

First Posted

April 14, 2016

Primary Completion

February 1, 2017

Last Updated

April 14, 2016

Record last verified: 2016-04

Locations